Tarsus Pharmaceuticals Inc. announced the appointment of David E. I. Pyott to its board of directors. Pyott brings decades of global leadership experience spanning innovative R&D, product development, and commercial execution, including a 17-year tenure as CEO of Allergan. Prior to Allergan, he served as head of the Novartis nutrition division and as a member of the executive committee of Novartis AG.

In addition to Tarsus, Pyott currently serves as a member of the board of directors of Alnylam Pharmaceuticals and Pliant Therapeutics. He was previously a member of the supervisory board of Royal Philips in the Netherlands and a member of the board of directors of BioMarin Pharmaceutical Inc. He is also chairman of the governing board of the London Business School, vice president and cofounder of the Ophthalmology Foundation, and a trustee of the California Institute of Technology.